Browsing Øvrige samlinger by Author "Røssevold, Andreas Hagen"

Now showing items 1-2 of 2

  • An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment 
    Tekpli, Xavier; Lien, Tonje Gulbrandsen; Røssevold, Andreas Hagen; Nebdal, Daniel J.H.; Borgen, Elin; Ohnstad, Hege Oma; Kyte, Jon A; Vallon-Christersson, Johan; Fongaard, Marie; Due, Eldri Undlien; Svartdal, Lisa Gregusson; Sveli, My Anh Tu; Garred, Øystein; Frigessi Di Rattalma, Arnoldo; Sahlberg, Kristine Kleivi; Sørlie, Therese; Russnes, Hege Elisabeth Giercksky; Naume, Bjørn; Kristensen, Vessela N. (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2019)
    How mixtures of immune cells associate with cancer cell phenotype and affect pathogenesis is still unclear. In 15 breast cancer gene expression datasets, we invariably identify three clusters of patients with gradual levels ...
  • Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial 
    Røssevold, Andreas Hagen; Andresen, Nikolai Kragøe; Bjerre, Christina Annette; Gilje, Bjørnar; Jakobsen, Erik Hugger; Raj, Sunil Xavier; Falk, Ragnhild Sørum; Russnes, Hege Elisabeth Giercksky; Jahr, Thea; Ruud, Randi Margit; Lømo, Jon; Garred, Øystein; Chauhan, Sudhir Kumar; Lereim, Ragnhild Reehorst; Dunn, Claire; Naume, Bjørn; Kyte, Jon A (Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2022)
    Immune checkpoint inhibitors have shown efficacy against metastatic triple-negative breast cancer (mTNBC) but only for PD-L1positive disease. The randomized, placebo-controlled ALICE trial (NCT03164993, 24 May 2017) evaluated ...